Table 2 Patient demographic and disease-related data and association with screening score
N = 208 | Mean score ± SD | Test/Test statistic | Significance | ||
|---|---|---|---|---|---|
Gender | male | 45.2% | 7.47 ± 2.413 | t-Test: t206 = 1.615 | p = .108 |
female | 54.8% | 6.89 ± 2.722 | p = .122 | ||
Age | Years; mean 63,47 ± 13,383 range 21–96 | 21–30 | 7.50 ± 2.121 | one-way ANOVA (groups): F(7, 200) = 1.654 | |
31–40 | 7.40 ± 1.776 | ||||
41–50 | 8.47 ± 2.452 | ||||
51–60 | 6.90 ± 2.564 | ||||
61–70 | 6.91 ± 2.914 | ||||
71–80 | 6.72 ± 2.447 | ||||
81–90 | 8.25 ± 2.236 | ||||
> 90 | 9.50 ± 0.707 | ||||
Performance status | ECOG 0 | 5.3% | 3.09 ± 1.044 | one-way ANOVA: F(4, 203) = 120.081 | p < 0.01 |
ECOG 1 | 30.8% | 5.02 ± 1.386 | |||
ECOG 2 | 23.6% | 6.78 ± 1.571 | |||
ECOG 3 | 19.7% | 8.93 ± 1.233 | |||
ECOG 4 | 20.7% | 10.09 ± 1.571 | |||
Primary diagnosis | Bronchial carcinoma | 16.3% | 7.00 ± 2.807 | one-way ANOVA: F(22, 185) = 1.405 | p = .166 |
Mammary carcinoma | 14.4% | 6.67 ± 2.758 | |||
Carcinoma of the female genital tract | 9.1% | 5.79 ± 2.149 | |||
Renal cell carcinoma | 5.3% | 7.36 ± 3.042 | |||
Myelomatosis | 4.8% | 5.70 ± 2.163 | |||
Leukemia | 4.8% | 6.30 ± 1.947 | |||
Colon cancer | 4.3% | 8.33 ± 2.179 | |||
Lymphoma | 4.3% | 6.56 ± 2.242 | |||
Esophageal cancer | 4.3% | 8.11 ± 1.453 | |||
Pancreatic carcinoma | 4.3% | 7.67 ± 2.598 | |||
others | 28.1% | 7.97 ± 2.575 | |||
Connection to PC | yes | 44.7% | 9.27 ± 1.695 | t-Test: t201 = −15.303 | p < 0.01 |
no | 52.9% | 5.44 ± 1.845 | |||
missing data | 2.4% | ||||
Decease during survey | yes | 30.3% | 8.59 ± 2.380 | t-Test: t206 = −5.643 | p < 0.01 |
no | 69.7% | 6.52 ± 2.441 |